Immunovant, Inc. · NASDAQ:IMVT
Immunovant — Corporate Update (April 2025)
27 slides from Immunovant's corporate update, Apr 21, 2025
Slide 1: Immunovant Corporate Update April 21, 2025
Immunovant Corporate Update April 21, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements Roivant Forward-Looking Statements Such forward looking statements include Immunovant’s expectations regarding the goals of its clinical development programs, including the efficacy, safety, and clinical success of batoclimab in Immunovant’s This presentation includes forw
Slide 3: Immunovant: Driving the Next Phase of Growth with Roivant
Immunovant: Driving the Next Phase of Growth with Roivant Management Transition Strategic Focus (Next Leg) IMVT-1402 Pipeline Update • Eric Venker, MD appointed CEO • Rapid clinical execution in • Sjögren’s Disease (SjD): IND (President & COO of Roivant) potentially registrational studies cleared, p
Slide 4: Introducing Eric Venker, MD as New CEO of Immunovant
Introducing Eric Venker, MD as New CEO of Immunovant Dr. Venker bring overs two decades of clinical practice and biopharma operating experience to the company Dr. Venker has served on the Board of Directors of Immunovant since 2020 and is also the President and Chief Operating Officer of Roivant. He
Slide 5: Clear Focus on Execution to Unlock Value Both Near and Long Term
Clear Focus on Execution to Unlock Value Both Near and Long Term Indication Study Data Catalyst 2025 2026 2027 2028 GD POC Remission Data Potentially TED Top Line Results Registrational Potentially ACPA+ D2T RA Open-label Period 1 Initial Results Registrational CLE POC Top Line Results Potentially A
Slide 6: IMVT-1402 Has Potential to be First- and Best-in-Class Across Multiple Indications
IMVT-1402 Has Potential to be First- and Best-in-Class Across Multiple Indications IMVT-1402 + Robust IgG lowering and Deep IgG Lowering Phase 1 data favorable safety profile drive + suggests deep dose-dependent + optimism for differentiation vs. IgG lowering; expected to reach ~80% other FcRn inhib
Slide 7: The Anti-FcRn Antibody Class Could Potentially be Broader than the TNF Class
The Anti-FcRn Antibody Class Could Potentially be Broader than the TNF Class Anti-FcRn antibodies, at the beginning of their development cycle, are already outpacing sales trajectory of TNF agents at a similar timepoint; a significant portion of TNF sales were driven by the later entrant, best-in-cl
Slide 8: Indication Strategy: Our FcRn Development Strategy is Designed for Maximum Commercial Potential
Indication Strategy: Our FcRn Development Strategy is Designed for Maximum Commercial Potential, Leveraging 1402’s Potentially Best-in-Class Clinical Profile • Expanding use of FcRn inhibitors to benefit greater number of patients with First-in-Class several new indications, with a potential efficac
Slide 9: Two New Indications for IMVT-1402 Driven by High Unmet Need and Disease Biology
Two New Indications for IMVT-1402 Driven by High Unmet Need and Disease Biology Sjögren’s Disease Cutaneous Lupus Erythematosus Best-in-Class Potential First-/Best-in-Class Potential Meaningful unmet need ~90K expected addressable US population ~75K expected addressable US 01 for subset of patients
Slide 10: Sjögren's Disease
Sjögren’s Disease Nearly-First- / Best-in-Class Opportunity
Slide 11: Sjögren's Disease (SjD) is an Autoimmune Disease Associated With A Myriad Of Clinical Manifestations
Sjögren's Disease (SjD) is an Autoimmune Disease Associated With A Myriad Of Clinical Manifestations Disease Awareness Common symptoms • SjD: a chronic autoimmune disease characterized by Dry eyes, mouths, lymphocytic infiltration of the salivary and lacrimal glands throat, and nose • Symptoms inclu
Slide 12: Autoantibodies Play Crucial Roles in Both the Diagnosis and Prognosis of SjD
Autoantibodies Play Crucial Roles in Both the Diagnosis and Prognosis of SjD Autoantibody Involvement Disease Pathogenesis3 • Serological abnormalities are common in SjD and include autoantibodies, hypergammaglobulinemia, and hypocomplementemia1 • Identification of disease-precipitating antibodies w
Slide 13: Publicly Available Nipocalimab Data Support Anti-FcRn Proof of Mechanism and Dose Response in SjD
Publicly Available Nipocalimab Data Support Anti-FcRn Proof of Mechanism and Dose Response in SjD Select results from a study of FcRn inhibition vs placebo in primary SjD LS mean (90%) change in Mean (SE) change in ClinESSDAI score at Week 24 ClinESSDAI score Placebo (n=56) Nipocalimab 5mg/kg Q2W (n
Slide 14: Sizable Patient Group with Unmet Need for an Approved Treatment Option
Sizable Patient Group with Unmet Need for an Approved Treatment Option Sizable Unmet Need Expansion Opportunities Potential to impact conditions Secondary Prevalence of Primary with shared autoimmune Sjögren’s Sjögren’s Disease: pathology 290K1 X Unmet need to improve Glandular Disease glandular man
Slide 15: Sjögren's Disease is a Potentially Best-in-Class Indication for Lead Asset IMVT-1402
Sjögren’s Disease is a Potentially Best-in-Class Indication for Lead Asset IMVT-1402 High Unmet No therapies are currently approved for the treatment of primary SjD Need Disease Autoantibody Autoantibodies detected in ~50-70% of patients with primary SjD; Pathology Anti-FcRn proof of mechanism estab
Slide 16: Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus First-/Best-in-Class Opportunity
Slide 17: Cutaneous Lupus Erythematosus (CLE), a Potential First-/Best-in-Class Opportunity in Dermatology
Cutaneous Lupus Erythematosus (CLE), a Potential First-/Best-in-Class Opportunity in Dermatology for IMVT-1402 with High Unmet Need CLE Characteristics1,2 Rare, chronic skin disease; prevalence of Subacute Chronic Lupus Chronic Cutaneous Lupus ~70/100,000 (234K in the US)3 Erythematosus (SCLE) Eryth
Slide 18: IMVT-1402: Disruption of CLE Pathophysiology Upstream by FcRn Inhibition
IMVT-1402: Disruption of CLE Pathophysiology Upstream by FcRn Inhibition CLE Pathogenesis and Anti-FcRn Upstream Mechanism Biology IMVT-1402 anti-FcRn technology provides upstream inhibition of inflammatory cascade triggered in cells by pathogenic antibodies and immune complexes • Potential to dampe
Slide 19: Dermatologists Desire a Skin-Focused, Targeted Biologic that Addresses CLE Unmet Needs
Dermatologists Desire a Skin-Focused, Targeted Biologic that Addresses CLE Unmet Needs1 IMVT-1402 has potential to be the first novel dermatology therapy for CLE in >50 years2 Considerable Market Opportunity Potential Differentiated Profile Dermatologists are frustrated by Targeted Biologic the skin
Slide 20: Case Study: 12-Week Treatment with IMVT-1402 in CLE
Case Study: 12-Week Treatment with IMVT-1402 in CLE • Female, 57 Observations • Subacute CLE and alopecia • Multiple skin locations affected • >60% reduction in CLASI-A score to 13 Demographics • CLASI – A score at screening = 36 by week 12 (Patient 1) • Background medication: • 5-point reduction in
Slide 21: IMVT-1402 is Potentially First-/Best-in-Class in CLE
IMVT-1402 is Potentially First-/Best-in-Class in CLE Untapped Market High unmet need with up to 50% of SCLE/CCLE patients failing standard of care Opportunity IgG and Immune Biologic, translational and mechanistic evidence support the critical role of IgG Complex Driven autoantibodies and immune com
Slide 22: Broad Development Program for IMVT-1402 with Trials Underway
Broad Development Program for IMVT-1402 with Trials Underway, Expected to Potentially Address >700K Patient Population Chronic Inflammatory Difficult-to-Treat Cutaneous Lupus Graves’ Disease Sjogren’s Disease Myasthenia Gravis Demyelinating Rheumatoid Arthritis Erythematosus Polyneuropathy Expected
Slide 23: Rich Catalyst Calendar
Rich Catalyst Calendar Program Vant Catalyst Expected Timing Roivant pipeline growth New mid/late-stage in-licensing announcements Ongoing LNP platform Markman hearing decision in Pfizer/BioNTech case 1H 2025* LNP platform Summary judgment phase in Moderna case 2Q-3Q 2025 Batoclimab Additional data
Slide 24: Thank you.
Thank you. roivant a = 7 ae ee ee ee ee
Slide 25: Appendix
Appendix roivant
Slide 26: Potentially Registrational Study with IMVT-1402 in SjD Enables Comparison of High Dose to Standard FcRn Inhibition
Potentially Registrational Study with IMVT-1402 in SjD Enables Comparison of High Dose to Standard FcRn Inhibition Inclusiona Treatment Period: up to 48 weeks Primary Endpoint • Adults with primary SjD N = 180 at Week 24: Period 1 Period 2* Change from • Moderate to severe (24 weeks) (24 weeks) base
Slide 27: Proof-of-Concept Study in CLE Designed to Demonstrate Short-Term and Long-Term Efficacy with IMVT-1402
Proof-of-Concept Study in CLE Designed to Demonstrate Short-Term and Long-Term Efficacy with IMVT-1402 Global – 56 Participants Inclusion Period 1 Period 2 Period 3 Blinded Open-Label Blinded Primary endpoint: • SCLE or CCLE, with or (12 wks) (14 wks) (26 wks) Percent change from without SLE baselin